Market Insights & Analysis from Kramer Capital Research

Don’t Lock in a Weak Defense When Wall Street Is Scoring Extra Points

October can be scary for investors. The biggest challenge of negotiating this season is staying open to the opportunities that lurk behind the shocks.

Take this week for example. Reading the headlines, you’d think the economy was in for an unprecedented nightmare ride.

People are so bearish that they’re dumping stocks that pay 3 percent yields to lock in what they see as safety in the Treasury market, where only the longest-term bonds pay more than 2 percent a year.

The calculus is as obvious as it gets. Those investors are convinced that such dividend-paying stocks are going to fall at least 1 percent in the near term to make bonds the smarter overall investment.

And once that’s your best scenario, you start hunting data points that back up your assumptions. After all, when you’ve already resigned to a scary experience, protecting yourself means anticipating every threat.

But when you only see threats, you’re truly planning for failure. That’s what people did early this week and why that strategy is backfiring now.

Too Much Safety is a Trap

My career started unforgettably with Black Monday in 1987. Every decade or so since then, the market has indulged its fear for a few months in autumn. We’ve discussed 1998, and you probably remember 2008.

Then there’s last October, when the trade war escalated. Apple Corp. (NASDAQ:AAPL) warned about its scaled-back outlook, the Treasury yield curve flattened and suddenly the air filled up with recession rumors. Stocks dropped 19.8 percent, skirting the bear market limit before recovering.

After a season like that, nobody wants to get caught by surprise. Everybody in the market is playing the strongest defense possible while bracing for economic disaster.

Don’t get me wrong. Defense is important. I laid out my best defensive line on Bloomberg TV yesterday. (Click here to watch the video.)

But when too many investors run for cover at once, the foxholes get crowded. Too much money flowing to safe havens can create its own bubble conditions. When those bubbles burst, it’s still shocking.

That’s what is happening here. People who have given up on the economy’s resilience at this point in the cycle have crowded into the absolute foxhole of Treasury bonds, paying higher prices and accepting that the yields they lock in will be lower.

When those yields get below a certain level, you start locking in a loss. The Fed already has set that threshold at their 2 percent inflation goal.

If you lock in less than 2 percent income, the Fed has guaranteed that your money will be worth less when your bonds mature. That’s a mathematical fact. The only two loopholes are if inflation never materializes or the fear gets more intense and bond prices rise.

The first scenario is a bet that the Fed, with all the resources at its disposal, will fail, taking interest rates all the way back to zero in the process. Even then, with prices rising 1.7 percent a year, you’re still locking in a loss.

Otherwise, the only reason to buy bonds now is because you’re speculating that you’ll be able to find someone more nervous than you who is willing to pay you more money in the future to take them off your hands.

In that scenario, you’re actually taking a significant risk. If the economy improves and you want to get back into the stock market, you’ll probably sell those bonds at a loss. Otherwise, you hold on and watch your purchasing power erode.

Either way, you won’t make money here just for being right. Everyone else has to be wrong. And that’s rarely anything like a sure thing.

Think about gold. While I love the security, since gold provides a way to preserve wealth, it’s historically a lousy way to make money unless you guess right and everyone else goes the wrong way.

At that point, you aren’t locking in anything. You aren’t even investing. You’re just gambling, with all the uncertainty and unpredictable outcomes that entails.

And while there’s nothing wrong with that, it’s a very different mindset from the reason most people stockpile bullion and park their money in Treasury bonds. They want liberation from risk, even if it means settling for a lower long-term return.

Meanwhile, you’re locking out everything else, bad and good. You’re locking out the normal upside stocks provided in the long haul, as well as the wildest year-to-year reversals along the way.

That’s why I pack a little scoring power into my defensive line, just so we can stay open to the upside if the economy keeps growing into next year and beyond.

(We haven’t even talked about my economic projections yet. They’re what I call “realistically bullish,” not spectacular but enough to keep stocks moving up.)

What stocks do I love? It depends on what you want. If you’re looking for pure defense, that Bloomberg interview provided a few of my perennial favorites but Value Authority has the full exclusive list of the ones I recommend to subscribers right now.

The average yield there is well above inflation, unlike Treasury bonds or even the S&P 500. And the stocks have done well even when you subtract the dividends we’ve received. We just booked another profitable exit today.

But if you truly believe that U.S. entrepreneurial spirit is alive and well, through economic boom and bust alike, you’ll want to stay open to long-term growth. The way to do that is through my GameChangers trading service.

Maybe simply want to grind a little profit out of other investors’ daily dithering. Click here now to watch my presentation about how you can profit in sideways markets, too.

CANNABIS CORNER: Make the Short Sellers Cry

When I see some of the most dynamic growth stocks in the world drop 40 percent in a four-month period, I know Wall Street’s negativity is overdone. That’s where Big Cannabis is today.

After all, stocks like Canopy Growth Corp. (NYSE:CGC) and Aurora Cannabis Inc. (NYSE:ACB) have been cut in half, but their underlying sales curves haven’t declined anywhere near that extent.

At the end of May, I thought CGC was looking for 200 percent revenue growth in the coming year. I admit now that I was a little too aggressive, even a tad naive.

Now it looks like this company will only boost its top line 170 percent in the next 12 months. I stand corrected. The numbers are still outrageous… they’re just a little less spectacular than we thought four months ago.

And that slightly more realistic outlook deserves a slightly less euphoric stock price. Four months ago, CGC at $54 commanded a multiple of 24X anticipated 2020 sales, which is an extreme number to fit an extreme stock.

Down here at $30, sales targets have come down 20% but the stock is down 45 percent for a multiple of 16X forward revenue. By historical standards, CGC is actually a bargain.

ACB and other Big Cannabis stocks tell a similar tale. And I think the relative “value” here makes people who bet against these companies on the downswing nervous.

Short interest on ACB has climbed to 14 percent of the entire stock. Those investors have committed to buy 133 million shares simply to cover their positions and get out.

At normal volume, it’s going to take weeks before they can get those shares. During that period, they’re vulnerable, even desperate.

CGC is even more oversold. Those short sellers need to buy back 19 percent of the company just to cover their positions. Again, that process will take weeks.

I suspect we’re going to make their lives a whole lot harder in my Turbo Trader Marijuana Millionaire Portfolio. If this is the bounce, we’re ready to boost our existing win rate and make more money.

Exclusive Report: 3 Biotech Breakthroughs To Bank On
X
Hilary Kramer
Legendary Wall St. trader Hilary Kramer

Where does the Smart Money look for the best biotech stocks? Small- and mid-cap biotechs. They're the ones with the ability to transform the world, and bring investors transformational profits. To get free access to Hilary Kramer's latest report, 3 Biotech Breakthroughs To Bank On, simply tell us where to send it in the box below.

Along with my FREE report, Hilary Kramer's 3 Biotech Breakthroughs to Bank On, please also send Hilary's free weekly e-letter, Trading Desk.
* We value your privacy. You will not be spammed, ever. Period.

Log In

Forgot Password

Search